Journal of Psychoactive Drugs
August 19, 2022
Marcio S. C. Longo, Bheatrix Bienemann, Marco Multedo et al.
10 citations
People who currently use ayahuasca/DMT, psilocybe mushrooms, LSD, cannabis, or MDMA/ecstasy score higher on nature relatedness than those who have never used these substances. After accounting for sociodemographic factors, only current and past use of ayahuasca/DMT remained positively associated with nature relatedness. Among those who reported an intention to use psilocybe mushrooms in the future, that intention was also linked to higher nature relatedness. The findings suggest that classic serotonergic psychedelics may have a unique relationship with nature relatedness, but the cross-sectional design cannot establish causation.
Trends in Psychiatry and Psychotherapy
October 18, 2022
Bheatrix Bienemann, Mariana Ridolfi, Marco Multedo et al.
5 citations
A validated scale for measuring ego dissolution demonstrated strong psychometric properties, though its factor structure may differ from the English version. Because validation is an ongoing process, further studies should compare ego dissolution scores across different substances and regions of the country.
Journal of Psychoactive Drugs
June 22, 2023
Bheatrix Bienemann, Amanda Rocha Barbosa, Lucas Villar Magalhães da Cruz et al.
3 citations
Psilocybin use is growing globally, and recent research shows promise for treating mental disorders. Analyzing 846 public online self-reports with textual analysis software, five clusters emerged describing mental experiences, cognitive processes, somatic experiences, perceptual alterations, and context of administration. The findings reinforce that psilocybin experiences commonly involve somatic and visual changes, feelings of connectedness and oneness with the world, the importance of setting, beneficial mystical experiences, and the phenomenon of ego dissolution. Understanding these circumstances may guide clinical use and harm reduction.